Advances in the Treatment of Bone Metastases

Cheryl D. Reich

metastases, neoplasm, pain, radiotherapy, bisphosphonates
CJON 2003, 7(6), 641-646. DOI: 10.1188/03.CJON.641-646

The skeleton is the third most common site for cancer to spread to after the liver and lungs. Malignancies that can cause destruction of skeletal bones include multiple myeloma and metastatic disease of the breast, prostate, and lung. Bone metastases are problematic for patients with cancer because accelerated bone breakdown occurs with many associated complications. One or more of the following problems may occur: pain, hypercalcemia, pathologic fractures, myelosuppression, and spinal cord compression with subsequent progressive immobility. Quality of life is affected negatively, and associated feelings of fear, grief, anger, despair, anxiety, and depression can occur. Management of malignancies of the bone involves a multimodal approach. Therapies include analgesia, hormone therapy, chemotherapy, surgery, radiation therapy, and the use of bisphosphonates. Nurses can be instrumental in promoting positive outcomes for patients with bone metastases.

Jump to a section


    Agency for Health Care Policy and Research. 1994. Management of cancer pain (Clinical practice guideline #9) [AHCPR Pub. #94-0592]. Rockville, MD: U. S. Department of Health and Human Services, Public Health Service.

    Barlogie, B. 1997. Multiple myeloma. Hematology/oncology clinics of North America monograph. Philadelphia: W. B. Saunders.

    Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., et al. 1998. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology, 16, 593-602.

    Body, J. J. 2000. Tumor bone disease and osteoporosis in cancer patients: Pathophysiology, diagnosis, and therapy. New York: Marcel Dekker.

    Coleman, R., Holen, I., Jagdav, S., Brown, J., Gutcher, S., Ellis, S., et al. 2001. Bone oncology. Retrieved February 13, 2002, from

    Coward, D. D., & Wilkie, D. J. 2002. Metastatic bone pain: Meanings associated with self-report and self-management decision making. Cancer Nursing, 23, 101-108.

    DeVita, V. T., Hellman, S., & Rosenberg, S. A. (Eds.) 2001. Cancer: Principles and practice of oncology (6th ed.) Philadelphia: Lippincott Williams and Wilkins.

    Fisher, G., Mayer, D. K., & Struthers, C. 1997. Bone metastases: Part I—Pathophysiology. Clinical Journal of Oncology Nursing, 1, 29-35.

    Fleisch, H. 1998. Bisphosphonates: Mechanisms of action. Endocrine Reviews, 19, 80-100.

    Fleish, H. 2000. Bisphosphonates in bone disease: From the laboratory to the patient (4th ed). San Diego, CA: Academic Press.

    Flounders, J. A., & Ott, B. B. 2003. Oncology emergency modules: Spinal cord compression. Oncology Nursing Forum, 30. Retrieved September 5, 2003, from

    Fourney, D. R., & Gokaslan, Z. L. 2003. Thoracolumbar spine: Surgical treatment of metastatic disease. Current Opinion in Orthopaedics, 14, 144-152.

    Gradisher, W. J., Mundy, G. R., & Harvey, H. A. 2001. Advanced breast cancer: Pathophysiology, diagnosis, and management of bone metastases. A Novartis Continuing Medical Education Monograph.

    Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K,. S., Lipton, A., et al. 2000. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. Retrieved February 13, 2002, from

    Hussein, M. A., Juturi, J. V., & Lieberman, I. 2002. Multiple myeloma: Present and future. Current Opinion in Oncology, 14, 31-35.

    Kanis, J. A., & McCloskey, E. V. 1997. Bone turnover and biochemical markers in malignancy. Cancer, 80(8 Suppl.), 1538-1545.

    Kyle, R. A. 2000. The role of bisphosphonates in multiple myeloma. Annals of Internal Medicine, 132, 734-736.

    Lipton, A., Demers, L., Curley, E., Chinchilli, V., Gaydos, L., Hortobagyi, G., et al. 1998. Markers of bone resorption in patients treated with pamidronate. European Journal of Cancer, 34, 2021-2026.

    Maxwell, T., Givant, E., & Kowalski, M. O. 2001. Exploring the management of bone metastasis according to the Roy Adaptation Model. Oncology Nursing Forum, 28, 1173-1181.

    Mayer, D. K., Struthers, C., & Fisher, G. 1997. Bone metastases: Part II—Nursing management Clinical Journal of Oncology Nursing, 1, 37-44.

    McCance, K. L., & Huether, S. E. 1998. Pathophysiology: The biologic basis for disease in adults and children (3rd ed.). St. Louis, MO: Mosby.

    Mercadante, S. 1997. Malignant bone pain: Pathophysiology and treatment. Pain, 69, 1-18.

    Mirels, H. 1989. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clinical Orthopaedics and Related Research, 249, 256-264.

    Mundy, G. R. 1995. Bone remodeling and its disorders. London: Martin Dunitz.

    Neeman, Z., & Wood, B. J. 2002. Radiofrequency ablation beyond the liver. Techniques in Vascular and Interventional Radiology, 5, 156-163.

    Nelson, J. B., Nabulsi, A. A., Vogelzang, N. J., Breul, J., Zonnenberg, B. A., Daliani, D. D., et al. 2003. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. Journal of Urology, 169, 1143-1149.

    Nielsen, O. S., Munro, A. J., & Tannock, I. F. 1991. Bone metastases: Pathophysiology and management policy. Journal of Clinical Oncology, 9, 509-524.

    Orr, F. W., Lee, J., Duivenvoorden, W., & Singh, G. 2000. Pathophysiologic interactions in skeletal metastases. Cancer, 88 (12 Suppl.), 2912-2918.

    Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., et al. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine, 346, 653-661.

    Rogers, M. J., Watts, D. J., & Russell, R. G. 1997. Overview of bisphosphonates. Cancer, 80 (8 Suppl.), 1652-1660.

    Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J. A., et al. 2001. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer Journal, 7, 377-387.

    Rubens, R. D. 1998. Bone metastases—The clinical problem. European Journal of Cancer, 34, 210-213.

    Schiff, D. 2003. Spinal cord compression. Neurologic Clinics, 21, 67-86.

    Schumacher, K. L., Koresawa, S., West, C., Dodd, M., Paul, S. M., Tripathy, D., et al. 2002. The usefulness of a daily pain management diary for outpatients with cancer-related pain. Oncology Nursing Forum, 29, 1304-1313.

    Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G., & Croucher, R. I. 1997. Bisphoshonates induce apoptosis in human myeloma cell lines: A novel anti-tumor activity. British Journal of Haematology, 98, 665-672.

    Smith, M. R. 2003. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs and Aging, 20, 175-183.

    Strohl, R. A. 2000. Bone metastases. In D. Camp-Sorrell & R. Hawkins (Eds.), Clinical manual for the oncology advanced practice nurse (pp. 611-614). Pittsburgh, PA: Oncology Nursing Society.

    Struthers, C., Mayer, D., & Fisher, G. 1998. Nursing management of the patient with bone metastases. Seminars in Oncology Nursing, 14, 199-209.

    Weinberger, B. 2000, May. Overcoming the obstacles of pain management. In 2000 Annual Congress-Symposia highlights (pp. 13-14). Expert panel held at the Oncology Nursing Society Annual Congress, San Antonio, TX.